Mind, Molecule, Market: Cannabis and Psychedelics in Mental Health

Mental health treatment is shifting fast, and two once-taboo categories now sit at the center of it. Cannabis and psychedelics are moving from the margins toward clinical legitimacy, with mounting evidence supporting their use for anxiety, depression, PTSD, and addiction. For the professionals shaping this space, the convergence of these two industries marks one of the most significant cannabis industry opportunities of the decade. This session maps where the two sectors intersect, and where they diverge. We'll examine the clinical pipelines advancing cannabinoids and compounds like psilocybin and MDMA, the funding flowing into both, and the cannabis market trends signaling where demand and capital are headed next. You'll see how operators, researchers, and investors are positioning early, before federal frameworks fully catch up. We'll also confront the hard parts: fragmented regulation, uneven clinical data, reimbursement gaps, and the reputational risk of moving too soon. Our experts translate these challenges into practical strategies, connecting science to commercial reality. You'll leave this session with an understanding of how mental health is reshaping both fields, and where your next move fits.